The Dexamethasone-Induced Inhibitor of Plasminogen Activator in Hepatoma Cells Is Antigenically-Related to an Inhibitor Produced by Bovine Aortic Endothelial Cells

David J Loskutoff; Karen Roegner; Larry A Erickson; Raymond R Schleef; Anna Huttenlocher; Patrick L Coleman; Thomas D Gelehrter

doi:10.1055/s-0038-1661436

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1986; 55(01): 008-011
DOI: 10.1055/s-0038-1661436

Original Article

Schattauer GmbH Stuttgart

The Dexamethasone-Induced Inhibitor of Plasminogen Activator in Hepatoma Cells Is Antigenically-Related to an Inhibitor Produced by Bovine Aortic Endothelial Cells

David J Loskutoff

The Department of Immunology, Scripps Clinic and Research Foundation, LaJolla, CA, USA

,

Karen Roegner

The Department of Immunology, Scripps Clinic and Research Foundation, LaJolla, CA, USA

,

Larry A Erickson

The Department of Immunology, Scripps Clinic and Research Foundation, LaJolla, CA, USA

,

Raymond R Schleef

The Department of Immunology, Scripps Clinic and Research Foundation, LaJolla, CA, USA

,

Anna Huttenlocher

¹The Departments of Internal Medicine and Human Genetics, University of Michigan Medical School, Ann Arbor, Ml, USA

,

Patrick L Coleman

¹The Departments of Internal Medicine and Human Genetics, University of Michigan Medical School, Ann Arbor, Ml, USA

,

Thomas D Gelehrter

¹The Departments of Internal Medicine and Human Genetics, University of Michigan Medical School, Ann Arbor, Ml, USA

› Author Affiliations

Abstract

PDF Download

Summary

Glucocorticoids decrease plasminogen activator (PA) activity in HTC rat hepatoma cells by inducing a specific inhibitor of PA activity (PAI). This inhibitor is similar in several biochemical properties to the PAI purified from bovine aortic endothelial cells (BAEs). We have used reverse fibrin autography and antiserum against BAE PAI to establish more fully the biochemical and immunological relationship of these inhibitors. Both inhibitors migrated with an apparent M_r of approximately 50,000, and the activity of both PAIs was stimulated by treatment with SDS suggesting that each of these molecules exists in both an active and a latent form. Antiserum to the BAE PAI immunoprecipi-tated all of the HTC PAI demonstrable by reverse fibrin autography. Finally, using this antiserum in a functional immunoassay, we have demonstrated that dexamethasone increases both active and latent PAI made by HTC cells. These results, indicate that HTC PAI and BAE PAI are antigenically as well as biochemically related molecules.

Key words

Plasminogen activator inhibitor - Bovine aortic endothelial cells - Rat hepatoma cells - Dexamethasone - Immunoprecipita-tion

PDF (383 kb)

References

References
1 Seifert SC, Gelehrter TD. Mechanism of glucocorticoid inhibition of plasminogen activator in rat hepatoma cells. Proc Natl Acad Sci USA 1978; 75: 6130-6133
2 Gelehrter TD, Barouski-Miller PA, Coleman PL, Cwikel BJ. Hormonal regulation of plasminogen activator in rat hepatoma cells. Mol Cell Biochem 1983; 53 (54) 11-21
3 Coleman PL, Barouski-Miller PA, Gelehrter TD. The dex-amethasone-induced inhibitor of fibrinolytic activity in hepatoma cells - a cellular product which specifically inhibits plasminogen activation. J Biol Chem 1982; 257: 4260-4264
4 Cwikel BJ, Barouski-Miller PA, Coleman PL, Gelehrter TD. Dexamethasone induction of an inhibitor of plasminogen activator in HTC rat hepatoma cells. J Biol Chem 1984; 259: 6847-6851
5 Loskutoff DJ, van Mourik JA, Erickson LA, Lawrence D. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci USA 1983; 80: 2956-2960
6 van Mourik JA, Lawrence DA, Loskutoff DJ. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem 1984; 259: 14914-14921
7 Hekman C, Loskutoff DJ. Endothelial cells produce a latent inhibitor of plasminogen activator that can be activated by denaturants. J Biol Chem 1985; 260: 11581-11587
8 Coleman PL, Green GD J. A sensitive, coupled assay for plasminogen activator using a thiol ester substrate for plasmin. Ann N Y Acad Sci 1981; 370: 617-626
9 Erickson LA, Lawrence DA, Loskutoff DJ. Reverse fibrin autography: A method to detect and partially characterize protease inhibitors after sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Anal Biochem 1984; 137: 454-463
10 Schleef RR, Sinha M, Loskutoff DJ. An immunoradiometric assay to measure the binding of a specific inhibitor of tissue-type plasminogen activator. J Lab Clin Med 1985; 106: 408-415
11 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254
12 Deutsch DG, Mertz ET. Plasminogen: purification from human plasma by affinity chromatography. Science 1970; 170: 1095-1096
13 Coleman PL, Patel PD, Cwikel BJ, Rafferty UR, Sznycer-Laszuk R, Gelehrter TD. Characterization of the dexamethasone-induced inhibitor of plasminogen activator in HTC hepatoma cells. J Biol Chem 1986 in press
14 Bennett WF. Two forms of tissue plasminogen activator (tPA) differ at a single specific glycosylation site. Thromb Haemostas 1983; 50: 106 Abstr
15 Travis J, Salvesen GS. Human plasma proteinase inhibitors. Ann Rev Biochem 1983; 52: 655-709
16 Philips M, Juul AG, Thorsen S. Human endothelial cells produce a plasminogen activator-inhibitor complex. Biochim Biophys Acta 1984; 802: 99-110
17 Sprengers ED, Verheijen JH, Van Hinsberg VW M, Emeis JJ. Evidence for the presence of two different fibrinolytic inhibitors in human endothelial cell conditioned medium. Biochim Biophys Acta 1984; 801: 163-171
18 Erickson LA, Hekman C, Loskutoff DJ. The primary plasminogen activator inhibitors in endothelial cells, platelets, serum, and plasma are immunologically related. Proc Natl Acad Sci USA 1986 in press
19 Erickson LA, Ginsberg MH, Loskutoff DJ. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest 1984; 74: 1465-1472
20 Kruithof EK O, Tran-Thang C, Ransijn A, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907-913
21 Verheijen JH, Chang GT G, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemostas 1984; 51: 392-395
22 Wiman B, Chmielewska J, Ranby M. Inactivation of tissue plasminogen activator in plasma. J Biol Chem 1984; 259: 3644-3647
23 Juhan-Vague I, Moerman B, DeCock F, Aillaud MF, Collen D. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb Res 1984; 33: 523-530
24 Kawano T, Morimoto K, Uemura Y. Partial purification and properties of urokinase inhibitor from human placenta. J. Biochem 1979; 67: 333-342
25 Christensen U, Holmberg L, Bladh B, Astedt B. Kinetics of the reaction between urokinase and an inhibitor of fibrinolysis from placental tissue. Thromb Haemostas 1982; 48: 24-26
26 Vassalli JD, Dayer JM, Wohlwend A, Belin D. Concomitant secretion of prourokinase and of a plasminogen activator-specific inhibitor by cultured human monocytemacrophages. J Exp Med 1984; 159: 1653-1668
27 Eaton DL, Scott RW, Baker JB. Purification of human fibroblast urokinase proenzyme and analysis of its regulation by proteases and protease nexin. J Biol Chem 1984; 259: 6241-6247